bca101,pembrolizumab
bicara,merck
['hanna', 'cohort i', 'bicara', 'cara thera']
we re grateful for the work &amp; contributions of dr. glenn hanna presenting most recent &amp; exciting data from bicara s phase 1/1b study of our dose expansion cohort in front-line r/m #hnscc at #asco2023 today. tune into our #webinar for more: 
Clinical stage biotech developing biologics that combine targeted therapy & immunotherapy to provide meaningful & safer therapies to cancer patients